New options are needed to vaccinate against deadly infectious agents such as HIV. Gene therapy could allow new vaccine approaches by precisely modifying the genome of human B lymphocytes (cells that naturally produce antibodies) by CRISPR molecular scissors. With this technique, it is thus possible to modify the specificity of immunoglobulin genes and to reprogram B cells to produce neutralizing antibodies against HIV-1. Still experimental, but recently confirmed by several laboratories, and supported by our preliminary data, this technique could become a powerful vaccine modality. We are equipping our ART platform (transfer research acceleration platform) with a MaxCyte electroporator and a protein imager to quickly implement preclinical protocols based on this new technology.